SyStemix (US) tests stem cell sorter in myeloma patients:
This article was originally published in Clinica
SyStemix (US) says it has approval to commence US and European trials of its haematopoeitic stem cell (HSC) sorter in multiple myeloma patients. Dr Chris Reading, director of cell processing at SyStemix, says the sorter can isolate HSCs at speeds up to 30,000 cell a second and can produce 90%-pure cell populations, free of tumour cells from multiple myeloma patients' blood, in a single step.
You may also be interested in...
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.